Cart
sales@molnova.com
BMS-681
CAS No. 847998-92-9
BMS-681( BMS 681 | BMS681 )
Catalog No. M16155 CAS No. 847998-92-9
A potent and orally bioavailable dual antagonist of CCR2 and CCR5 with binding IC50 of 0.7 nM and 2.4 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS-681
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and orally bioavailable dual antagonist of CCR2 and CCR5 with binding IC50 of 0.7 nM and 2.4 nM, respectively.
-
DescriptionA potent and orally bioavailable dual antagonist of CCR2 and CCR5 with binding IC50 of 0.7 nM and 2.4 nM, respectively; exhibits high selectivity against other chemokine receptors and GPCRs; shows CCR2 functional assays of monocyte chemotaxis (IC50=0.24 nM) and CD11b upregulation (whole blood IC50=4.7 nM), CCR5 functional assays of human T-cells (IC50=2.3 nM) and whole blood CCR5-mediated CD11b upregulation (IC50=4.3 nM); suitable for use in both murine and monkey models of inflammation.
-
In Vitro——
-
In Vivo——
-
SynonymsBMS 681 | BMS681
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number847998-92-9
-
Formula Weight491.603
-
Molecular FormulaC26H36F3N5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCC1CC(CCC1N2CCC(C2=O)NC3=NC=NC4=C3C=C(C=C4)C(F)(F)F)N(C)C(C)C
-
Chemical Name1-((1S,2R,4R)-4-(isopropyl(methyl)amino)-2-propylcyclohexyl)-3-((6-(trifluoromethyl)quinazolin-4-yl)amino)pyrrolidin-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zheng Y, et al. Nature. 2016 Dec 15;540(7633):458-461.
2. Carter PH, et al. ACS Med Chem Lett. 2015 Mar 4;6(4):439-44.
molnova catalog
related products
-
LMD-009
LMD-009 (LMD 009, LMD009) is a potent, selective, nonpeptide CCR8 agonist.
-
CCX-354
CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases.
-
Ladarixin sodium
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.
